Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer.

Authors: Yuan, Jian-Min; Chan, Kenneth K; Coetzee, Gerhard A; Castelao, J Esteban; Watson, Mary A; Bell, Douglas A; Wang, Renwei; Yu, Mimi C

Published In Carcinogenesis, (2008 Jul)

Abstract: Genetically determined factors that alter the metabolism of tobacco carcinogens can influence an individual's susceptibility to bladder cancer. The associations between the genotypes of glutathione S-transferase (GST) M1, GSTP1, GSTT1 and N-acetyltransferase (NAT) 1 and the phenotypes of NAT2 and cytochrome P450 (CYP) 1A2 and bladder cancer risk were examined in a case-control study involving 731 bladder cancer patients and 740 control subjects in Los Angeles County, California. Individual null/low-activity genotypes of GSTM1, GSTT1 and GSTP1 were associated with a 19-48% increase in odds ratio (OR) of bladder cancer. The strongest association was noted for GSTM1 [OR for the null genotype = 1.48, 95% confidence interval (CI) = 1.19-1.83]. When the three GST genes were examined together, there was a monotonic, statistically significant association between increasing number of null/low-activity genotypes and risk (P for trend = 0.002). OR (95% CI) for one and two or more null/low-activity GST genotypes was 1.42 (1.12-1.81) and 1.71 (1.25-2.34), respectively, relative to the absence of null/low-activity GST genotype. NAT2 slow acetylation was associated with doubled risk of bladder cancer among individuals with known high exposures to carcinogenic arylamines (OR = 2.03, 95% CI = 1.12-3.69, P = 0.02). The effect of NAT2 slow acetylation was even stronger in the presence of two or more null/low-activity GST genotypes. There were no associations between bladder cancer risk and NAT1 genotype or CYP1A2 phenotype.

PubMed ID: 18544563 Exiting the NIEHS site

MeSH Terms: Adult; Arylamine N-Acetyltransferase/genetics; Arylamine N-Acetyltransferase/metabolism; Carcinogens/metabolism*; Carcinoma, Transitional Cell/chemically induced; Carcinoma, Transitional Cell/enzymology; Carcinoma, Transitional Cell/genetics; Case-Control Studies; Cytochrome P-450 CYP1A2/genetics; Cytochrome P-450 CYP1A2/metabolism; Female; Genetic Predisposition to Disease; Glutathione Transferase/genetics; Glutathione Transferase/metabolism; Humans; Isoenzymes/genetics; Isoenzymes/metabolism; Male; Middle Aged; Urinary Bladder Neoplasms/chemically induced; Urinary Bladder Neoplasms/enzymology*; Urinary Bladder Neoplasms/genetics*; Urinary Bladder/drug effects; Urinary Bladder/enzymology

to Top